SCSalma Alejandra Beltran Covarrubias

Salma Alejandra Beltran Covarrubias

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Salma Alejandra Beltran Covarrubias has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Mandibular Advancement Device vs Continuous Positive Airway Pressure in Obstructive Sleep Apnea: An Updated Systematic Review and Meta-analysis

    by Lorena M. Murrieta Bruciaga, Alejandro Chen Liang, Yeison Cruz Castillo, Italibi M. Sibilla Chacon, Salma A. Beltran, Arnold Ocoró-Vallecilla, Domenica Alejandra Herrera Hernandez, Maria Ali, Izabela Turcu, Ernesto Calderón Martínez

  • Open Access

    Ascorbic acid as an adjunct therapy for anemia in erythropoietin-treated hemodialysis patients: a systematic review and meta-analysis

    by Salma Alejandra Beltrán Covarrubias, Angelo Magallanes Bajana, Alejandro Chen Liang, Yeison Cruz Castillo, Montserrat Villa Sánchez, España De la Rosa Valdez, Michelle Sámano Sánchez, Shreya Shambhavi, Vaidarshi Abbagoni, Oscar Yasser Pena Zapata, et al.

    Background: Anemia is a common complication in chronic kidney disease (CKD), especially in hemodialysis patients, causing fatigue and reduced quality of life. Standard treatments involve iron and erythropoietin (EPO). Ascorbic acid (vitamin C) supports iron metabolism by converting ferric to ferrous iron and enhancing absorption and mobilization. This systematic review and meta-analysis evaluated the effectiveness of ascorbic acid in improving hematologic and iron parameters in adult anemic patients undergoing maintenance hemodialysis. Methods: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a comprehensive search was performed in PubMed, EMBASE, Cochrane, Scopus, Web of Science, CINAHL and Google Scholar through May 2025. Only randomized controlled trials and crossover studies assessing ascorbic acid in adult anemic hemodialysis patients were included. The protocol was registered in the International Prospective Register of Systematic Review (PROSPERO) (CRD420251056337). Primary outcomes were hemoglobin (Hb), ferritin, serum iron, transferrin saturation (TSAT) and total iron-binding capacity (TIBC). Meta-analyses used DerSimonian-Laird random-effects models. Results: Of 479 screened articles, 14 studies were included. Ascorbic acid supplementation was associated with a modest but significant increase in Hb [mean difference (MD) 0.94 g/dL; 95% confidence interval (CI) 0.57 to 1.31; P < .01; I² = 87.2%] and TSAT (MD 6.86%; 95% CI 1.93 to 11.78; P < .01; I² = 96.7%). Ferritin levels showed a slight but significant reduction (MD −65.00 ng/mL; 95% CI −117.20 to −12.80; P = .01; I² = 57.2%), along with a decrease in TIBC (MD −22.54 µg/dL; 95% CI −42.37 to −2.72; P = .03; I² = 76.1%). EPO requirements expressed as units/kg/week were significantly reduced (MD −21.29; 95% CI −27.73 to −14.84; P < .01; I² = 0.0%). No significant changes were observed in serum iron levels or EPO dosage expressed as IU/week. Conclusion: Ascorbic acid supplementation may confer modest hematologic benefits in hemodialysis patients with improvements in Hb, TSAT and iron utilization, and a small reduction in weight-adjusted erythropoiesis-stimulating agent dose. However, the certainty of evidence is low, and long-term safety and patient-centered outcomes remain unestablished.


  • Oral isotretinoin combined with antihistaminics for the treatment of acne vulgaris: a systematic review, meta-analysis and trial sequential analysis with GRADE assessment of randomized controlled trials

    by Camila Sanchez Cruz, Salma Alejandra Beltran Covarrubias, Alejandro Chen Liang, Montserrat Villa Sanchez, Yeison Cruz Castillo, España De la Rosa Valdez, Frances Marie Mejia, Robin Picavia, Ernesto Calderón-Martinez